85 related articles for article (PubMed ID: 17635500)
1. Interaction between midazolam and clarithromycin in the elderly.
Quinney SK; Haehner BD; Rhoades MB; Lin Z; Gorski JC; Hall SD
Br J Clin Pharmacol; 2008 Jan; 65(1):98-109. PubMed ID: 17635500
[TBL] [Abstract][Full Text] [Related]
2. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.
Belle DJ; Callaghan JT; Gorski JC; Maya JF; Mousa O; Wrighton SA; Hall SD
Br J Clin Pharmacol; 2002 Jan; 53(1):67-74. PubMed ID: 11849197
[TBL] [Abstract][Full Text] [Related]
3. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
Nassr N; Lahu G; von Richter O; Reutter F; Knoerzer D; Zech K; Erb KA; Schug B; Blume H; Hermann R
Br J Clin Pharmacol; 2007 Mar; 63(3):365-70. PubMed ID: 16981901
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers.
van Rongen A; Kervezee L; Brill M; van Meir H; den Hartigh J; Guchelaar HJ; Meijer JH; Burggraaf J; van Oosterhout F
CPT Pharmacometrics Syst Pharmacol; 2015 Aug; 4(8):454-64. PubMed ID: 26380154
[TBL] [Abstract][Full Text] [Related]
5. Interaction between midazolam and clarithromycin: comparison with azithromycin.
Yeates RA; Laufen H; Zimmermann T
Int J Clin Pharmacol Ther; 1996 Sep; 34(9):400-5. PubMed ID: 8880291
[TBL] [Abstract][Full Text] [Related]
6. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
7. A potentially hazardous interaction between erythromycin and midazolam.
Olkkola KT; Aranko K; Luurila H; Hiller A; Saarnivaara L; Himberg JJ; Neuvonen PJ
Clin Pharmacol Ther; 1993 Mar; 53(3):298-305. PubMed ID: 8453848
[TBL] [Abstract][Full Text] [Related]
8. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.
Markert C; Schweizer Y; Hellwig R; Wirsching T; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
Br J Clin Pharmacol; 2014 Jan; 77(1):141-8. PubMed ID: 23738582
[TBL] [Abstract][Full Text] [Related]
9. Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.
Stoll F; Burhenne J; Lausecker B; Weiss J; Thomsen T; Haefeli WE; Mikus G
J Clin Pharmacol; 2013 Nov; 53(11):1199-204. PubMed ID: 23939663
[TBL] [Abstract][Full Text] [Related]
10. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.
Markert C; Hellwig R; Burhenne J; Hoffmann MM; Weiss J; Mikus G; Haefeli WE
Eur J Clin Pharmacol; 2013 Oct; 69(10):1785-93. PubMed ID: 23748747
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
12. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.
Quinney SK; Malireddy SR; Vuppalanchi R; Hamman MA; Chalasani N; Gorski JC; Hall SD
Eur J Clin Pharmacol; 2013 Mar; 69(3):439-48. PubMed ID: 22777148
[TBL] [Abstract][Full Text] [Related]
13. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
Olkkola KT; Ahonen J; Neuvonen PJ
Anesth Analg; 1996 Mar; 82(3):511-6. PubMed ID: 8623953
[TBL] [Abstract][Full Text] [Related]
14. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Hanke N; Frechen S; Moj D; Britz H; Eissing T; Wendl T; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):647-659. PubMed ID: 30091221
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin.
Yeates RA; Laufen H; Zimmermann T; Schumacher T
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):577-9. PubMed ID: 9455717
[TBL] [Abstract][Full Text] [Related]
17. Effect of itraconazole on the pharmacokinetics of atorvastatin.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
[TBL] [Abstract][Full Text] [Related]
18. Safety and Tolerability of Antimicrobial Agents in the Older Patient.
Soraci L; Cherubini A; Paoletti L; Filippelli G; Luciani F; Laganà P; Gambuzza ME; Filicetti E; Corsonello A; Lattanzio F
Drugs Aging; 2023 Jun; 40(6):499-526. PubMed ID: 36976501
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone.
Wendl T; Frechen S; Gerisch M; Heinig R; Eissing T
CPT Pharmacometrics Syst Pharmacol; 2022 Feb; 11(2):199-211. PubMed ID: 34783193
[TBL] [Abstract][Full Text] [Related]
20. Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions.
Sodhi JK; Huang CH; Benet LZ
Clin Pharmacokinet; 2021 Feb; 60(2):205-222. PubMed ID: 32725383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
